Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Perion Reports First Quarter 2019 Results

Published

on

Reading Time: 9 minutes

Search Business Positive Trajectory Continues: Third Consecutive
Quarter of Sequential Growth; Year-over-Year Growth for the First Time
in Five Years;

Strong Cash Flow Continues: Company Raises Full Year Adjusted EBITDA
Guidance to $24M – $26M and Further Strengthens Balance Sheet with Early
Redemption of Convertible Bonds

TEL AVIV, Israel & NEW YORK–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24PERI&src=ctag” target=”_blank”gt;$PERIlt;/agt; lt;a href=”https://twitter.com/hashtag/Perion?src=hash” target=”_blank”gt;#Perionlt;/agt;–Perion Network Ltd. (NASDAQ: PERI), a global technology company that
delivers synchronized digital marketing solutions for advertisers and
publishers through the world’s largest channels – digital advertising,
social media, and search, announced today its financial results for the
first quarter ended March 31, 2019.

Financial Highlights*

(In millions, except per share data)

         
      Three months ended
March 31,
2018       2019
Advertising revenues $     29.3 $     18.6
Search and other revenues $ 31.6 $ 35.2
Total Revenues $ 60.9 $ 53.8
GAAP Net Income $ 0.1 $ 1.2
Non-GAAP Net Income $ 3.0 $ 3.3
Adjusted EBITDA $ 4.3 $ 5.1
Net cash provided by operating activities $ 14.6 $ 14.0
GAAP Diluted Earnings Per Share $ 0.00 $ 0.05
Non-GAAP Diluted Earnings Per Share $ 0.12 $ 0.13
                             

* Reconciliation of GAAP to Non-GAAP measures follows.

Doron Gerstel, Perion’s CEO stated, “Our ongoing efforts to drive
innovation and deepen partnerships in our Search business, is winning in
the market. By leveraging our strategic relationship with Microsoft
Bing, exploring new monetization opportunities and increasing search
demand, the new leadership at CodeFuel has delivered its third
consecutive quarter of sequential growth and the first quarter of
year-over-year growth in five years; we expect this positive trend to
continue.”

This significant progress has meaningfully expanded the immediate and
longer-term importance of our Search business,” added Mr. Gerstel. “Our
increased Search revenues and strong cash flow enable us to continue our
planned investments in our advertising offering, to further
differentiate Undertone in a growing but evolving market.”

Undertones’ Synchronized Digital Branding solution was enhanced by the
acquisition of Captain Growth, which will provide the AI optimization
engine required to offer brands the critical ability to put their
best-performing units in front of the right users at the right time –
for unprecedented cross-channel engagement,” Mr. Gerstel continued. “We
are excited by the acceptance of our customers and believe in a unique
opportunity to differentiate Undertone in this space.”

Mr. Gerstel concluded, “As a result of the strong start of 2019, where
we achieved higher than planned first quarter Adjusted EBITDA combined
with our current visibility, we feel confident to increase our annual
guidance of Adjusted EBITDA from $22-$24 million to $24-$26 million. The
increased Adjusted EBITDA guidance and our improved free cash flow, a
result of our recent cost optimization efforts, and the current cash
position, we decided to early repay our bonds and further strengthen our
balance sheet.”

Financial Comparison for the First Quarter of 2019:

Revenues: Revenues declined by 12%, from $60.9 million in the
first quarter of 2018 to $53.8 million in the first quarter of 2019.
This decline was primarily a result of a 37% decline in Advertising
revenues as a result of the transition from selling formats to holistic
solution. Despite of the decline in revenues, our gross margin in the
Advertising business increased year over year as we prioritize margins
and profitability over sales. Search and other revenues increased 12% in
the first quarter of 2019 as a result of the addition of new publishers,
higher revenue-per-mile and increased number of searches.

Customer Acquisition Costs and Media Buy (“CAC”): CAC in
the first quarter of 2019 were $27.4 million, or 51% of revenues, as
compared to $31.9 million, or 52% of revenues in the first quarter of
2018.

Net Income: On a GAAP basis, net income in the first quarter of
2019 was $1.2 million, as compared to a net income of $0.1 million in
the first quarter of 2018.

Non-GAAP Net Income: In the first quarter of 2019, non-GAAP net
income was $3.3 million, or 6.0% of revenues, compared to the $3.0
million, or 5.0% of revenues, in the first quarter of 2018.

Adjusted EBITDA: In the first quarter of 2019, Adjusted EBITDA
was $5.1 million, or 9.5% of revenues, compared to $4.3 million, or 7.0%
of revenues, in the first quarter of 2018.

Cash and Cash Flow from Operations: As of March 31, 2019, cash
and cash equivalents and short-term deposit were $45.1 million. Cash
provided by operations in the first quarter of 2019 was $14.0 million,
compared to $14.6 million in the first quarter of 2018.

Short-term Debt, Long-term Debt and Convertible Debt: As of March
31, 2019, total debt was $31.0 million, compared to $40.5 million at
December 31, 2018.

Perion satisfies all the financial covenants associated with its public
debt.

2019 Guidance:

Management has increased its previously issued Adjusted EBITDA guidance
of $22 million to $24 million for the full year of 2019 to $24 million
to $26 million.

Conference Call:

Perion management will host a conference call to discuss the results
today at 9 a.m. ET. Details are as follows:

  • Conference ID: 5831485
  • Dial-in number from within the United States: 1-888-394-8218
  • Dial-in number from Israel: 1-809-212-883
  • Dial-in number (other international): 1-323-701-0225
  • Playback available until May 22, 2019 by calling 1-844-512-2921
    (United States) or 1-412-317-6671 (international). Please use PIN code
    5831485 for the replay.
  • Link to the live webcast accessible at https://www.perion.com/ir-info/

About Perion Network Ltd.

Perion is a global technology company that delivers advertising
solutions to brands and publishers. Perion is committed to providing
data-driven execution, from high-impact ad formats to branded search and
a unified social and mobile programmatic platform. More information
about Perion may be found at www.perion.com,
and follow Perion on Twitter @perionnetwork.

Non-GAAP measures

Non-GAAP financial measures consist of GAAP financial measures adjusted
to exclude acquisition related expenses, share-based compensation
expenses, restructuring costs, loss from discontinued operations,
accretion of acquisition related contingent consideration, impairment of
goodwill, amortization and impairment of acquired intangible assets and
the related taxes thereon, non-recurring expenses, foreign exchange
gains (losses) associated with ASC-842, as well as certain accounting
entries under the business combination accounting rules that require us
to recognize a legal performance obligation related to revenue
arrangements of an acquired entity based on its fair value at the date
of acquisition. Additionally, in September 2014, the Company issued
convertible bonds denominated in New Israeli Shekels and at the same
time entered into a derivative arrangement (SWAP) that economically
exchanges the convertible bonds as if they were denominated in US
dollars when the bonds were issued. The Company excludes from its GAAP
financial measures the fair value revaluations of both, the convertible
bonds and the related derivative instrument, and by doing so, the
non-GAAP measures reflect the Company’s results as if the convertible
bonds were originally issued and denominated in US dollars, which is the
Company’s functional currency. Adjusted Earnings Before Interest, Taxes,
Depreciation and Amortization (“Adjusted EBITDA”) is defined as
operating income excluding stock-based compensation expenses,
depreciation, restructuring costs, acquisition related items consisting
of amortization of intangible assets and goodwill and intangible asset
impairments, acquisition related expenses, gains and losses recognized
on changes in the fair value of contingent consideration arrangements
and certain accounting entries under the business combination accounting
rules that require us to recognize a legal performance obligation
related to revenue arrangements of an acquired entity based on its fair
value at the date of acquisition.

The purpose of such adjustments is to give an indication of our
performance exclusive of non-cash charges and other items that are
considered by management to be outside of our core operating results.
These non-GAAP measures are among the primary factors management uses in
planning for and forecasting future periods. Furthermore, the non-GAAP
measures are regularly used internally to understand, manage and
evaluate our business and make operating decisions, and we believe that
they are useful to investors as a consistent and comparable measure of
the ongoing performance of our business. However, our non-GAAP financial
measures are not meant to be considered in isolation or as a substitute
for comparable GAAP measures, and should be read only in conjunction
with our consolidated financial statements prepared in accordance with
GAAP. Additionally, these non-GAAP financial measures may differ
materially from the non-GAAP financial measures used by other companies.
A reconciliation between results on a GAAP and non-GAAP basis is
provided in the last table of this press release.

Forward Looking Statements

This press release contains historical information and forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995 with respect to the business, financial condition and
results of operations of Perion. The words “will”, “believe,” “expect,”
“intend,” “plan,” “should” and similar expressions are intended to
identify forward-looking statements. Such statements reflect the current
views, assumptions and expectations of Perion with respect to future
events and are subject to risks and uncertainties. Many factors could
cause the actual results, performance or achievements of Perion to be
materially different from any future results, performance or
achievements that may be expressed or implied by such forward-looking
statements, or financial information, including, among others, the
failure to realize the anticipated benefits of companies and businesses
we acquired and may acquire in the future, risks entailed in integrating
the companies and businesses we acquire, including employee retention
and customer acceptance; the risk that such transactions will divert
management and other resources from the ongoing operations of the
business or otherwise disrupt the conduct of those businesses, potential
litigation associated with such transactions, and general risks
associated with the business of Perion including intense and frequent
changes in the markets in which the businesses operate and in general
economic and business conditions, loss of key customers, unpredictable
sales cycles, competitive pressures, market acceptance of new products,
inability to meet efficiency and cost reduction objectives, changes in
business strategy and various other factors, whether referenced or not
referenced in this press release. Various other risks and uncertainties
may affect Perion and its results of operations, as described in reports
filed by Perion with the Securities and Exchange Commission from time to
time, including its annual report on Form 20-F for the year ended
December 31, 2018 filed with the SEC on March 19, 2019. Perion does not
assume any obligation to update these forward-looking statements.

   

 

PERION NETWORK LTD. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF OPERATIONS

In thousands (except share and per share data)

 
Three months ended
March 31,
2018     2019
Unaudited Unaudited
Revenues:
Advertising $ 29,295 $ 18,584
Search and other   31,610   35,265
Total Revenues   60,905   53,849
 
Costs and Expenses:
Cost of revenues 6,056 5,766
Customer acquisition costs and media buy 31,885 27,433
Research and development 5,544 4,862
Selling and marketing 9,701 8,325
General and administrative 4,286 3,058
Depreciation and amortization 2,071 2,390
Restructuring costs   1,138  
Total Costs and Expenses   60,681   51,834
 
Income from Operations 224 2,015
Financial expense, net   607   1,325
 
Income (Loss) before Taxes on income (383) 690
Tax benefit   440   542
 
Net Income $ 57 $ 1,232
 
 
Net Earnings per Share

Basic

$ 0.00 $ 0.05
Diluted $ 0.00 $ 0.05
Weighted average number of shares
Basic   25,850,023   25,883,768
Diluted   25,850,023   25,885,029
 
         

PERION NETWORK LTD. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

In thousands

 
December 31, March 31,
2018 2019
Audited Unaudited
ASSETS
 
Current Assets:
Cash and cash equivalents $ 39,109 $ 38,386
Short-term bank deposit 4,000 6,700
Accounts receivable, net 55,557 40,159
Prepaid expenses and other current assets   5,227   5,420
Total Current Assets 103,893 90,665
 
Property and equipment, net 15,649 14,537
Operating lease right-of-use assets 24,889
Goodwill and intangible assets, net 131,547 131,661
Deferred taxes 4,414 4,960
Other assets   943   723
 
Total Assets $ 256,446 $ 267,435
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
 
Current Liabilities:
Accounts payable $ 38,208 $ 35,297
Accrued expenses and other liabilities 17,240 14,514
Short-term operating lease liability 4,226
Short-term loans and current maturities of long-term and Convertible
debt
16,059 16,385
Deferred revenues 3,794 3,417
Payment obligation related to acquisitions   1,813   1,200
Total Current Liabilities 77,114 75,039
Long-Term Liabilities:
Long-term debt, net of current maturities 16,667 14,583
Convertible debt, net of current maturities 7,726
Long-term operating lease liability 21,367
Other long-term liabilities   6,158   5,762
Total Liabilities   107,665   116,751
 
Shareholders’ equity:
Ordinary shares 211 211
Additional paid-in capital 239,693 240,285
Treasury shares at cost (1,002) (1,002)
Accumulated other comprehensive gain 142 221
Accumulated deficit   (90,263)   (89,031)
Total Shareholders’ Equity   148,781   150,684
 
Total Liabilities and Shareholders’ Equity $ 256,446 $ 267,435
 
     

PERION NETWORK LTD. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands

 

Three months ended
March 31,

2018     2019
Unaudited     Unaudited

Operating activities:

Net Income $ 57 $ 1,232
 

Adjustments required to reconcile net income to net cash
provided
by operating activities:

Depreciation and amortization 2,071 2,390
Share-based compensation expense 618 463
Foreign currency translation 67 19
Accrued interest, net 128 (199)
Deferred taxes, net (354) (546)
Accrued severance pay, net (626) (316)
Fair value revaluation – convertible debt (986) 699
Net changes in operating assets and liabilities   13,621   10,246
Net cash provided by operating activities $ 14,596 $ 13,988

Investing activities:

Purchases of property and equipment, net $ (90) $ (227)
Capitalization of development costs (688)
Short-term deposits, net   5,909   (2,700)
Net cash provided by (used in) investing activities $ 5,131 $ (2,927)

Financing activities:

Exercise of stock options and restricted share units 129
Payment made in connection with acquisition (1,813)
Repayment of convertible debt (7,901)
Repayment of long-term loans   (9,630)   (2,083)
Net cash used in financing activities $ (9,630) $ (11,668)
Effect of exchange rate changes on cash and cash equivalents and
restricted cash
  74   (110)
Net increase (decrease) in cash and cash equivalents and
restricted cash
10,171 (717)
Cash and cash equivalents and restricted cash at beginning of year   32,755   40,803
Cash and cash equivalents and restricted cash at end of year $ 42,926 $ 40,086
 
     

PERION NETWORK LTD. AND ITS SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS: UNAUDITED

In thousands (except share and per share data)

 

Three months ended
March 31,
2018       2019
Unaudited Unaudited
 
GAAP Net Income $ 57 $ 1,232
Share based compensation 618 463
Amortization of acquired intangible assets 1,204 1,046
Restructuring costs 1,138
Non-recurring Legal fees 235 257
Fair value revaluation of convertible debt and related derivative 127 267
Foreign exchange losses associated with ASC-842 292
Taxes on the above items   (361)   (303)
Non-GAAP Net Income $ 3,018 $ 3,254
 
Non-GAAP Net Income $ 3,018 $ 3,254
Taxes on income (79) (239)
Financial expense, net 480 766
Depreciation   867   1,344
Adjusted EBITDA $ 4,286 $ 5,125
 
Non-GAAP diluted earnings per share $ 0.12 $ 0.13
 
Shares used in computing non-GAAP diluted earnings per share   25,852,909   25,908,734
 

Contacts

Perion Network Ltd.
Investor relations
Hila Barenboim
+972
(73) 398-1000
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland

Published

on

Continue Reading

Cannabis

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

Published

on

Continue Reading

Innocan

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Published

on

innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial:-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey

HERZLIYA, Israel and ALGARY, AB, May 9, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan’s innovative therapy provided immediate noticeable pain relief and improved mobility.

Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri’s condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her.

As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed.

“Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia,” commented Iris Bincovich, CEO of Innocan. “Once again, Innocan has shown liposomal-CBD to be effectively active for pain relief and well-being. We see this pre-clinical treatment as strong evidence of liposomal-CBD’s potential to improve the lives of animal patients and potentially human patients.”

“Laminitis is a crippling condition well familiar and common in horses,” said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan. “The disease results in severe pain condition, representing another big market for liposomal-CBD with great potential to treat horses. Innocan is dedicated to advancing the development of CBD-based therapeutics for various indications in both humans and animals.”

For further information and a supporting video, please see: https://youtu.be/Hgqh2WOlwJQ?si=oGgSYrGi3rkW-RC

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+1 5162104025

+972-54-3012842

+442037699377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey-302141590.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania